This article has Open Peer Review reports available.
Hepato-protective effects and chemical constituents of a bioactive fraction of the traditional compound medicine-Gurigumu-7
© The Author(s). 2016
Received: 29 August 2015
Accepted: 3 June 2016
Published: 13 June 2016
Gurigumu-7 is an important traditional Mongolian medicine frequently used for liver diseases. However, the pharmacological effects and the bioactive constituents are not well understood.
This research was to use CCl4-induced liver damage in mice to investigate the hepatoprotective effects of Gurigumu-7 and the methanol eluted fraction from a DIAION column of an extract of Gurigumu-7 (MF). The chemical constituents of MF were analyzed by UPLC-MS.
Pretreated orally with MF (66, 132 and 264 mg/kg) once a day for 4 days dose-dependently suppressed CCl4-induced mice liver histopathological changes and serum aminotransferase activities (alanine transaminase: 1144.0 ± 787.2 v.s. 2461.8 ± 1072.7 U/L, p < 0.05; aspartate transaminase: 1173 ± 785.3 v.s. 2506.6 ± 1140.7 U/L, p < 0.01). MF treated group demonstrated increased levels of SOD (108.19 ± 30.32 v.s. 75.75 ± 5.37 U/mg protein, p < 0.01) but decreased levels of malonyldialdehyde (7.68 ± 1.95 v.s. 44.32 ± 16.68 nmol/mg protein, p < 0.01) compared to the CCl4 control group. More than 30 chemical constituents were quantified, and MF was found to be rich in ellagic acid (297.97 mg/g), luteolin and its glucosides (35.10 mg/g), apigenin and its glucosides (>30 mg/g), ursolic acid (14.91 mg/g), bidenoside C (8.75 mg/g), and proanthocyanidins (15.64 mg/g in proanthocyanidin A2 equivalent).
The methanol eluted fraction (MF) from a DIAION column of an extract of the Mongolian medicine-Gurigumu-7 was found to be more hepatoprotective than Gurigumu-7. The results suggested that MF is a promising bioactive fraction for the development of new hepatoprotective medicine with better formulation and quality control properties.
Gurigumu-7 is an ethnic compound medicine frequently used for liver diseases in the Mongolian and Tibetan traditional medical settings. It is comprised of seven individual traditional medicines, the flower of Carthamus tinctorius L. (Safflower), the fruit of Terminalia chebula Retz. (Fructus chebulae), the flower of Scabiosa comosa Fisch. ex Roem. & Schult. (Flos scabiosae), the aerial part of Ephedra sinica Stapf (Herba ephedrae), the aerial part of Viola yezoensis Maxim. (Herba violae), gypsum and the caulis of Clematis armandii Franch (Caulis clematidis armandii).
Safflower is one of the most frequently used herbal drugs found in traditional medicine prescriptions for its function to improve circulation and lower blood pressure [1, 2]. The major flavonoid constituents of safflower were reported to have hepatoprotective effects on CCl4-induced liver injury . Fructus chebulae has been used in traditional medicine for intestinal and hepatic detoxification, diarrhea, cough, sore throat and various ailments . Fructus chebulae is rich in phenolic compounds which were reported to have anti-viral activities against hepatitis C and other viruses [5–7]. Flos scabiosae is used mainly for liver diseases in traditional medicine . Phenolics [9, 10] and triterpene compounds  were reported as the bioactive constituents of Flos scabiosae. Herba ephedrae has been used to relief symptoms of colds  due to the nasal decongesting and bronchodilating effects of its alkaloid constituents, ephedrine and related compounds. However, these sympathomimetic alkaloids may cause side effects to central nervous system. Renewed interest in herba ephedrae has come from new pharmacological findings that this herb could decrease uraemic toxins and showed anti-inflammatory activity due to its proanthocyanidin constituents [13–16]. Herba violae has been used for boils, carbuncles, hepatitis and other infections in traditional Chinese medicine . The flavonoid constituents were reported to be the bioactive constituents of Herba violae for antibacterial and antioxidant activities [18–20]. Caulis clematidis armandii has been traditionally used mainly for inflammatory-associated diseases and the phenolic constituents were reported to be its bioactive constituents [21, 22]. Gurigumu-7 was reported have the effect to decrease serum aminotransferase activities in CCl4-induced mice . However, the bioactive fraction, bioactive constituents and mechanism of action of Gurigumu-7 have not been revealed.
Composed of 7 raw materials, Gurigumu-7 has to be administered in large volumes and the taste is unpleasant. Moreover, it is hard to establish a quality control method for Gurigumu-7, as each of the component herbal medicine could contain hundreds of chemical constituents. It is necessary to find out the bioactive fraction for the possibility to reduce the dosage and to simplify the quality control method. In the present study, we used macroporous resin to separate Gurigumu-7 extract to 3 fractions and tested the hepatoprotective effects of these fractions. The most active fraction, MF (methanol eluted fraction), was further investigated in detail for its in vivo protective effects on liver damage induced by carbon tetrachloride and compared the effect with Gurigumu-7. The chemical constituents, antioxidant activity and ability to increase liver antioxidase load of MF were also investigated.
Chemicals and instruments
Extraction solvents were of analytical grade from XiLong chemical Co. Ltd. (Guangdong, China). Silymarin was obtained from Sigma-Aldrich (SIGMA-ALDRICH, Co., China) and used as a positive control in this research. UPLC-DAD-ESI-MS experiments were performed on an Agilent 1290 infinity UPLC system (Agilent, USA). Absorbance was measured with a microplate reader (DNM-9602, Beijing Pu Long new technology Co. Ltd., Beijing, China). A wan-neng pulverizer (Zhejiang Yi Li Co. Ltd., Zhejiang, China) was used for grinding medicines.
The seven medicines to formulate Gurigumu-7 in this research were supplied by Kulun Mongolian medicine factory, Inner Mongolia, China and identified by the authors through examining the morphological characteristics, anlyzing the UHPLC-MS of the plant extracts, and considering the information provided by the supplier. The voucher specimens were stored in the Laboratory of Natural Products & Functional Foods, College of Life Sciences, Inner Mongolia University, China, as followings: the flower of Carthamus tinctorius L (voucher specimen number NPFFC-2); the fruit of Terminalia chebula Retz (voucher specimen NPFFT-1); Gypsum (99.5 % of CaSO4•2H2O content as determined by the method described in Chinese pharmacopeia, voucher specimen number NPFFG-1); the aerial part of Ephedra sinica Stapf (voucher specimen number NPFFE-1); the aerial part of Viola yezoensis Maxim (voucher specimen number NPFFV-1); the flower of Scabiosa comosa Fisch. ex Roem. & Schult. (voucher specimen number NPFFS-1); the caulis of Clematis armandii Franch (voucher specimen number NPFFC-3).
Preparation of samples
Gurigumu-7 was prepared according to the documented prescription  by mixing the individual medicines in the following ratio: Safflower 25 g – Gypsum 15 g – Herba ephedrae 15 g – Herba violae 15 g – Fructus chebulae 15 g – Flos scabiosae 10 g – Caulis clematidis armandii 10 g, and grinding the mixture to powder.
MF (methanol eluted fraction from a DIAION column of Gurigumu-7 extract) was prepared as following: Gurigumu-7 was extracted with methanol under reflux (70 °C) for three times (2 h, 1 h and 30 min, respectively). The pooled methanol solution was concentrated under vacuum (40 °C) to get the methanol extract (10.33 g) which was subjected to a macroporous resin (DIAION HP20) column eluted with H2O, H2O–MeOH 1:1 and MeOH. The MeOH eluted part was concentrated under vacuum (40 °C) to get MF as a brown powder (1.78 g).
Animals and treatments
Six-week-old male scxk (meng) 2002–0001 mice (weighing 30 ± 5 g) were purchased from the Animal Center of Inner Mongolia University, China. The mice were housed in clean cages accessing to food and water ad libitum and acclimated to the temperature (22 ± 2 °C) with 12 h light/dark cycles for one week. The animals were cared for in accordance with the “guidelines for animal experiments” and the experimental procedures were approved by the Animal Ethics Committee of Inner Mongolia University (approval number 2016004). One hundred and twenty mice were randomly divided into two groups named experiment 1 and 2 (e1 and e2). E1 and e2 were further randomly divided into six groups with ten mice in each group, respectively. Mice of groups 1 and 2 from e1 and e2 were given with 0.5 ml saline/day, group 3 from e1 and e2 were given with 17 mg/kg silymarin. Groups 4, 5 and 6 from e1 were treated with Gurigumu-7 powder (270.84, 541.68, 1083.36 mg/kg, respectively). Groups 4, 5 and 6 from e2 were treated with 66, 132 and 264 mg/kg of MF, respectively. Each group received the appropriate vehicle or sample daily by gastric intubations for 4 days. After 1 h of the medication in the forth day, CCl4 (125 μl, 1 % in oil) was given by intraperitoneal injection to mice except for the mice in group 1 which were given oil only. Whole blood was collected for biochemical analysis from the orbit 16 h later after drug administration, and the liver tissue was cut and immediately fixed in 10 % neutral formalin for histopathology study.
The blood samples were put standing for one hour and the serum was separated by centrifugation (WiseSpin®Personal Table Top Centrifuges, CF-10, DAIHAN Scientific, Co., Ltd) under 12225 g for 5 min. Serum alanine transaminase (ALT) and aspartate transaminase (AST) were measured in Hospital of Inner Mongolia University using standard clinical method.
Determination of malondialdehyde (MDA) and superoxide dismutase (SOD) in liver homogenate
The liver tissue samples were homogenized with cold saline. The homogenates were centrifuged at 3000 rpm at 4 °C for 10 min and the supernatant was kept at −80 °C until use. The supernatant was used for the measurement of MDA and SOD using commercial kits (Jiancheng Institute of Biotechnology, Nanjing, China) following the supplier’s instructions.
Liver tissues from e2 were fixed in 10 % (v/v) neutral phosphate buffer formalin and the liver pathological section were prepared and examined by the First Affiliated Hospital of Inner Mongolia Medical University – Cancer Hospital.
DPPH radical scavenging assay
Where Acontrol was the average absorbance of wells without sample.
Results represented as EC50 (sample concentration that produced 50 % of radical scavenging activity) were found from the S%-versus-concentration curves.
Preparation of Sample Solutions for UPLC-DAD-MS Analysis
The 3 fractions of Gurigumu-7 were dissolved in DMSO (10 μg:1 ml) containing 1 μg/mL of abrusin 2″-O-β-apioside  as internal standard. Standard stock solutions were prepared in DMSO containing 1 μg/mL of internal standard. The solutions were filtrated through 0.22 μm microfilters to obtain the sample solutions for ultra-high performance liquid chromatography-diode array detector-triple quadruple mass spectrometry (UPLC-DAD-QQQMS) analysis.
The chemical compositions of the three fractions from a DIAION column chromatography of Gurigumu-7 were analyzed by UPLC-DAD-QQQMS using an Agilent ZORBAX SB-C18 RRHT column (50 × 2.1 mm i.d.; particle size 1.8 μm) at 30 °C. The constituents were quantified by UHPLC-QQQMS in multiple reaction monitoring (MRM) mode using reported analysis conditions and standard compounds for the constituents of Safflower [26, 27], Fructus chebulae , Flos scabiosae , Herba ephedrae , and Herba violae [20, 30]. For the quantification of calceorioside B in Caulis clematidis armandii, ESIMS full scan method was used and the extract was compared with a standard compound from Beijing Century Aoke Biotechnology Co. Ltd (Beijing, China). Data were presented as the average values from three repeat quantifications.
Measurement of proanthocyanidin A2 equivalents
Proanthocyanidin A2 equivalents were measured by n-BuOH–HCl–Fe III method [31, 32]. Briefly, to a 1.5 ml centrifuge tube was added 0.5 mg of sample, 1.2 ml of a solution of n-BuOH-conc. HCl (95:5, v/v) and 40 μl of ferric ammonium sulphate reagent (2 % w/v in 2 M HCl). The tubes were closely capped with top clips and heated at 95 °C for 40 min. Absorbance of the released cyanidin was measured at 560 nm by a Thermo Scientific Varioskan Flash (Thermo Fisher Scientific Oy D.O. Box100, FI-01621 Vantaa, Finland). The flavan-3-ol contents were expressed as proanthocyanidin A2 equivalents as A-type proanthocyanidins were reported from one of the medicines in Gurigumu-7, Herba ephedrae [15, 16]. Proanthocyanidin A2 equivalents of samples were calculated from the absorbance – concentration curve of proanthocyanidin A2.
Statistical analysis of the data was accomplished by mean of the SPSS® statistical software package. The data are presented as the means ± SD. Differences where P < 0.05 were considered statistically significant.
The effect of gurigumu-7 and MF on the increased levels of serum transaminases induced with CCl4
Effects of Gurigumu-7 powder on serum transaminases in CCl4-injured mice (e1)
32.1 ± 8.4##
141.6 ± 59.0##
3822.0 ± 1494.8
4059.6 ± 1408.3
CCl4-17 mg/kg silymarin-treated mice
2205.0 ± 912.2*
2034.0 ± 1262.9*
CCl4-270.84 mg/kg Gurigumu-7 -treated mice
3438.0 ± 1742.0
3586.0 ± 2170.1
CCl4-541.68 mg/kg Gurigumu-7-treated mice
2933.2 ± 1405.0
2910.0 ± 1652.8
CCl4-1083.36 mg/kg Gurigumu-7 -treated mice
2345.1 ± 1449.8
2290.2 ± 1519.7*
Effects of MF on serum transaminases in CCl4-injured mice (e2)
30.4 ± 4.0##
123.0 ± 24.3##
2461.8 ± 1072.7
2506.6 ± 1140.7
CCl4-17 mg/kg silymarin-treated mice
1115.6 ± 291.3**
1230.6 ± 437.6**
CCl4-66 mg/kg MF-treated mice
2766.0 ± 1909.7
2482.8 ± 1853.3
CCl4-132 mg/kg MF-treated mice
1929.0 ± 799.8
1748.0 ± 694.8
CCl4-264 mg/kg MF-treated mice
1144.0 ± 787.2*
1173 ± 785.3**
Effects on Superoxide Dismutase (SOD) and Malondialdehyde (MDA) levels
Liver SOD and MDA levels in mouse treated with CCl4 and MF
SOD (U/mg protein)
MDA (nmol/mg protein)
114.23 ± 2.75##
7.08 ± 0.04##
75.75 ± 5.37
44.32 ± 16.68
CCl4-17 mg/kg silymarin treated mice
102.41 ± 24.66*
12.47 ± 3.27**
CCl4-66 mg/kg MF treated mice
82.46 ± 15.48
19.31 ± 6.58**
CCl4-132 mg/kg MF treated mice
93.39 ± 40.91
8.58 ± 1.11**
CCl4-264 mg/kg MF treated mice
108.19 ± 30.32**
7.68 ± 1.95**
Histopathological changes of mice livers
Components of MF
Concentrations (mg/g unless otherwise indicated) of Gurigumu-7 constituents in the three fractions
0.00 ± 0.00
1.61 ± 0.01
1.15 ± 0.00
hydroxysafflor yellow A
12.77 ± 0.01
0.19 ± 0.02
0.17 ± 0.00
2.09 ± 0.00
0.08 ± 0.01
0.082 ± 0.04
3.13 ± 0.01
8.75 ± 0.01
0.06 ± 0.01
0.65 ± 0.05
2.86 ± 0.04
1.63 ± 0.02
0.22 ± 0.02
0.28 ± 0.039
0.04 ± 0.03
0.21 ± 0.03
26.2 ± 0.09
0.20 ± 0.08
25.5 ± 0.13
0.36 ± 0.07
0.38 ± 0.10
3.13 ± 0.09
12.81 ± 0.02
0.74 ± 0.00
0.076 ± 0.00
7.68 ± 0.02
12.23 ± 0.02
0.09 ± 0.00
0.67 ± 0.01
0.09 ± 0.00
0.24 ± 0.01
0.48 ± 0.01
0.24 ± 0.01
2.35 ± 0.01
1.88 ± 0.01
3.48 ± 0.01
7.30 ± 0.02
3.50 ± 0.02
2.25 ± 0.01
6.05 ± 0.01
2.38 ± 0.01
0.86 ± 0.01
1.06 ± 0.01
0.94 ± 0.02
82.14 ± 0.80
297.97 ± 1.84
0.46 ± 0.00
2.28 ± 0.01
0.87 ± 0.01
32.08 ± 0.58
0.83 ± 0.02
0.24 ± 0.00
0.34 ± 0.00
0.67 ± 0.01
5.54 ± 0.01
0.64 ± 0.01
0.98 ± 0.01
4.30 ± 0.01
0.05 ± 0.00
0.75 ± 0.00
5.38 ± 0.02
11.59 ± 0.02
11.51 ± 0.01
0.73 ± 0.00
16.02 ± 0.02
0.84 ± 0.01
16.12 ± 0.02
2.96 ± 0.02
1.59 ± 0.01
14.91 ± 0.35
0.01 ± 0.019
0.01 ± 0.02
1.80 ± 0.03
98.33 ± 0.15 %a
1.67 ± 0.64 %a
Proanthocyanidin A2 equivalent
31.33 ± 2.62
15.64 ± 1.78
25.23 ± 0.74
3.12 ± 0.02
0.67 ± 0.01
0.54 ± 0.53 %a
90.81 ± 1.01 %a
8.65 ± 0.87 %a
apigenin 6-C-β-D-glucosyl-8-C- α-L-arabinoside/apigenin 6-C-β- D- glucosyl-8-C-β-L-arabinoside
2.88 ± 0.36 %a
48.96 ± 0.08 %a
48.16 ± 0.65 %a
apigenin 6-C-α-L-arabinosyl- 8-C-β-D-xyloside/apigenin 6,8-di-C-α-L-arabinoside
2.66 ± 0.08 %a
47.50 ± 0.45 %a
49.83 ± 0.71 %a
Caulis clematidis armandii
0.18 ± 0.89
0.17 ± 0.07
DPPH scavenging activity of a methanolic extract of Gurigumu-7 and MF
percentage of DPPH scavenged at different concentration
methanolic extract of Gurigumu-7
protocatechuic acid (positive control)
MF demonstrated stronger DPPH scavenging activity (EC50 = 39.79 μg/mL) than Gurigumu-7 extract (EC50 = 43.69 μg/mL), which may come from the high contents of phenolic compounds such as ellagic acid and the flavonoids, luteolin and its glucosides, as well as apigenin and its glucosides in MF (Table 5).
The ethnic compound medicine, Gurigumu-7, has a long history to be used for liver diseases in Mongolian and Tibetan medical clinics . The formulations of Gurigumu-7 on the market are bitter and astringent powder or bolus with a large dosage indicated (5 g every time for example). They are unpleasant to swallow and the administration may affect appetites. In this study, we separated Gurigumu-7 extract into three fractions by DIAION column and found MF, the methanol eluted fraction, demonstrated better bioactivity than Gurigumu-7. From 10.33 g of Gurigumu-7 extract, 1.78 g of MF was obtained, and indeed, a much lower dose (264 mg/kg) of MF showed more potent hepato-protective activity than Gurigumu-7 at 1083.36 mg/kg. These results indicated that MF is one of the hepato-protective fractions of gurigumu-7, and that administration of MF could reduce the effective dose.
It is reported that liver tissue in CCl4 treated animals can cause lipid peroxidation and trigger production of MDA. Measurement of MDA levels is the most commonly used method for the evaluation of lipid peroxidation, because MDA is the most abundant individual aldehyde resulting from lipid peroxidation . Our study showed that acute CCl4 treatment caused an increase of liver MDA concentration which was in agreement with reported result . Pretreatment with MF at the doses of 66, 132, 264 mg/kg for four consecutive days reversed these changes. SOD which is an important in vivo antioxidant enzyme is inactivated by lipid peroxides or reactive oxygen species when CCl4 is administrated . In the MF treated groups, a tendency of dose-dependent-increase of SOD activities was observed, with the effect of 264 mg · kg−1 being highly significant (P < 0.01). The strong DPPH scavenging activity of MF, and the increased liver SOD and decreased liver MDA levels of MF treated groups suggest that the hepatoprotective effects of MF are partly due to its antioxidant effects.
Chemical analysis revealed that MF contained large amounts of triterpene compound-ursolic acid, as well as phenolic compounds-ellagic acid and flavonoids (glycosides of apigenin, luteolin and quercetin). All these natural products are known to have hepatoprotective activities [37–39]. The active fraction of Gurigumu 7, MF, with better antioxidant and hepatoprotective activity in a much less dosage than Gurigumu 7, could be a better choice for patients.
In conclusion, this study demonstrated for the first time that the methanol eluted fraction (MF) from a DIAION column of an extract of the Mongolian medicinal prescription-Gurigumu-7 has hepatoprotective effect. MF dose dependently decreased serum aminotransferase activities, increased liver SOD levels and decreased liver malonyldialdehyde levels in CCl4 treated mice. MF was found to contain large amounts of bioactive phenolic compounds and triterpenes which might act concertedly for the hepatoprotective effects. The research results provided scientific evidence for the clinic efficacy of this Mongolian medicinal prescription for liver diseases. The results demonstrated that MF is a promising bioactive fraction of Gurigumu-7 for the develpment of convenient hepatoprotective formulations.
A, absorbance; ALT, alanine transaminase; AST, aspartate transaminase; EC50, 50 % effective concentration; MDA, malonyldialdehyde; MF, the methanol eluted fraction from a DIAION column of an extract of Gurigumu-7; MRM, multiple reaction monitoring; SOD, superoxide dismutase; UPLC-DAD-QQQMS, ultra-high performance liquid chromatography-diode array detector-triple quadruple mass spectrometry
We would like to express our sincere thanks Liu Yang and Qianqian He for helping with the animal experiment. We would also like to thank the Hospital of Inner Mongolia University and the First Affiliated Hospital of Inner Mongolia Medical University - cancer hospital for caring out serum ALT, AST and pathological assessments.
This work was supported by the National Natural Science Foundation of China (No. 81160511).
Availability of data and materials
The data and materials of this article are included within the article.
CMM and HYX designed the study and wrote the paper; HYX, QM, JNM, ZGW and YLW performed the experiments. HYX and CMM analyzed data. All authors read and approved the final version of the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The animals were cared for in accordance with the “guidelines for animal experiments” and the experimental procedures were approved by the Animal Ethics Committee of Inner Mongolia University (approval number 2016004).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Chinese Pharmacopoeia Committee. Drug standards of Ministry of public health of China (Mongolian medicine Fascicule). Beijing: Chemical Industry Press; 1998. p. 194.Google Scholar
- Yang DH, Ren XL, Xu F, Ma X-Q, Liu G-X, Li C-H, Li C, Cai S-Q. Absorptive constituents and their metabolites in drug-containing urine samples from Wuzhishan miniature pigs orally administered with Buyang Huanwu decoction. J Nat Med. 2014;68:11–21.View ArticlePubMedGoogle Scholar
- Wang Y, Tang C, Zhang H. Hepatoprotective effects of kaempferol 3-O-rutinoside and kaempferol 3-O-glucoside from Carthamus tinctorius L. on CCl4-induced oxidative liver injury in mice. J Food Drug Anal. 2015;23:310–7.View ArticleGoogle Scholar
- China Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China, vol. 1. Beijing: Chemical Industry Press; 2010. p. 173–4.Google Scholar
- Pellati F, Bruni R, Righi D, Grandini A, Tognolini M, Pio Prencipe F, Poli F, Benvenuti S, Del Rio D, Rossi D. Metabolite profiling of polyphenols in a Terminalia chebula Retzius ayurvedic decoction and evaluation of its chemopreventive activity. J Ethnopharmacol. 2013;147:277–85.View ArticlePubMedGoogle Scholar
- Ajala OS, Jukov A, Ma C-M. Hepatitis C virus inhibitory hydrolysable tannins from the fruits of Terminalia chebula. Fitoterapia. 2014;99:117–23.View ArticlePubMedGoogle Scholar
- Lin LT, Chen TY, Lin SC, Chun CY, Lin TC, Wang GH, Anderson R, Lin CC, Richardson CD. Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry. BMC Microbiol. 2013;13:187–202.View ArticlePubMedPubMed CentralGoogle Scholar
- Chinese Pharmacopoeia Committee. Drug standards of Ministry of public health of China (Mongolian medicine Fascicule). Beijing: Chemical Industry Press; 1998. p. 52.Google Scholar
- Wang G, Zhao Z, Xue P, Ma F, Zhang D, Wang N, Li M. Chemical constituents from flowers of Scabiosa tschilliensis. Zhongguo Zhong yao za zhi. 2015;40:807–13.PubMedGoogle Scholar
- Ma J-N, Bolraa S, Ji M, He Q-Q, Ma C-M. Quantification and antioxidant and anti-HCV activities of the constituents from the inflorescences of Scabiosa comosa and S. Tschilliensis. Nat Prod Res. 2016;30:590–4.View ArticlePubMedGoogle Scholar
- Ji M, Li SJ, Ma CM. Chemical constituents of the inflorescence of Scabiosa comosa Fisch and their antioxide and α-glucosidase inhibitory activities. J Inner Mongolia Univ (Natural Science Edition). 2014;4:398–403.Google Scholar
- China Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China, vol. 1. Beijing: Chemical Industry Press; 2010. p. 300–1.Google Scholar
- Yokozawa T, Fujioka K, Oura H, Tanaka T, Nonaka GI, Nishioka I. Decrease in uraemic toxins, a newly found beneficial effect of Ephedrae Herba. Phytother Res. 1995;9:382–4.View ArticleGoogle Scholar
- Kim IS, Park YJ, Yoon SJ, Lee HB. Ephedrannin A and B from roots of Ephedra sinica inhibit lipopolysaccharide-induced inflammatory mediators by suppressing nuclear factor-kB activation in RAW 264.7 macrophages. Int Immunopharmacol. 2010;10:1616–25.View ArticlePubMedGoogle Scholar
- Tao HM, Wang LS, Cui ZC, Zhao DQ, Liu YH. Dimeric proanthocyanidins from the roots of Ephedra sinica. Planta Med. 2008;74:1823–5.View ArticlePubMedGoogle Scholar
- Zang X, Shang M, Xu F, Liang J, Wang X, Mikage M, Cai S. A-Type proanthocyanidins from the stems of Ephedra sinica (Ephedraceae) and their antimicrobial activities. Molecules. 2013;18:5172–89.View ArticlePubMedGoogle Scholar
- China Pharmacopoeia Committee. Pharmacopoeia of the People’s Republic of China, vol. 1. Beijing: Chemical Industry Press; 2010. p. 317.Google Scholar
- Xie C, Veitch NC, Houghton PJ, Simmonds MSJ. Flavone C-glycosides from Viola yedoensis Makino. Chem Pharm Bull. 2003;51:1204–7.View ArticlePubMedGoogle Scholar
- Li DG, Zhang WG, Song YM, Li HF, Wu HJ, Jin YP, Zhou L. Studies on antibacterial constituents in Viola yedoensis. J Northwest Sci-TechUniv Agri For (Nat Sci Ed). 2006;34:87–90.Google Scholar
- Cao J, Yin C, Qin Y, Cheng Z, Chen D. Approach to the study of flavone di-C-glycosides by high performance liquid chromatography-tandem ion trap mass spectrometry and its application to characterization of flavonoid composition in Viola yedoensis. J Mass Spectr. 2014;49:1010–24.View ArticleGoogle Scholar
- Editorial board of Chinese herb medicine. Chinese herbal medicine. Shanghai: Shanghai science and Technology Press; 1999. p. 3•477–8.Google Scholar
- Xiong J, Bui V-B, Liu X-H, Hong Z-L, Yang G-X, Hu J-F. Lignans from the stems of Clematis armandii (“Chuan-Mu-Tong”) and their anti-neuroinflammatory activities. J Ethnopharmacol. 2014;153:737–43.View ArticlePubMedGoogle Scholar
- Qi J, Zhang J, Sun Q, Li X, He P. Protective functions of traditional Mongolian medicines on experimental liver Injury. Acta Acad Med Nei Mongol. 1994;16:82–6.Google Scholar
- Ma JN, Wang SL, Zhan K, Wu Z-G, Hattori M, Chen G-L, Ma C-M. Chemical components and antioxidant activity of the peels of commercial apple-shaped pear (fruit of Pyrus pyrifolia cv. pingguoli). J Food Sci. 2012;77:C1097–102.View ArticlePubMedGoogle Scholar
- Ma C-M, Nakamura N, Hattori M. Saponins and C-glycosyl flavones from the seeds of Abrus precatorius. Chem Pharm Bull. 1998;46:982–7.View ArticleGoogle Scholar
- Yerigui, Bumandorj B, Byambaakhuu N, Ma C-M. Pharmacokinetics of five different types of Safflower constituents in rat plasma after oral administration of Safflower powder. J Liq Chromatogr R T. 2015;38:1740–6.View ArticleGoogle Scholar
- He Q-Q, Yang L, Zhang J-Y, Ma J-N, Ma C-M. Chemical constituents of gold-red apple and their α-glucosidase inhibitory activities. J Food Sci. 2014;79:C1970–83.View ArticlePubMedGoogle Scholar
- Wang CX, Yue LL, Xu HY, Uneer, Huang Y, Zhang H-P, Gao J, Ma C-M. Simultaneous quantification of 7 components in different punica granatum parts using ultra-high performance liquid chromatography-triple quadrupole mass spectrometry (UPLC-QQQMS). Food Science, published on line first.Google Scholar
- Wei P, Huo H, Ma Q, Li H, Xing X, Tan X, Luo J. Pharmacokinetic comparisons of five ephedrine alkaloids following oral administration of four different Mahuang-Guizhi herb-pair aqueous extracts ratios in rats. J Ethnopharmacol. 2014;155:642–8.View ArticlePubMedGoogle Scholar
- Zhang L, Li M-Y, Wang L-W, Gao J, Ma C-M. Isolation, identification, quantification and inhibitory activity on HCV protease of coumarins from Viola yedoensis. Can Chem Trans. 2013;1:157–64.View ArticleGoogle Scholar
- Porter LJ, Hrstich LN, Chan BG. The conversion of procyanidins and prodelphinidins to cyanidin and delphinidin. Phytochemistry. 1986;25:223–30.View ArticleGoogle Scholar
- Ma CM, Sato N, Li XY, Nakamura N, Hattori M. Flavan-3-ol contents, anti-oxidative and α-glucosidase inhibitory activities of Cynomorium songaricum. Food Chem. 2010;118:116–9.View ArticleGoogle Scholar
- Fridovich I. Superoxide dismutases: defence against endogenous superoxide radical. Ciba Found Symp. 1978;65:77–93.PubMedGoogle Scholar
- Cemek M, Aymelek F, Buyukokuroglu ME, Karaca T, Buyukben A, Yilmaz F. Protective potential of Royal jelly against carbon tetrachloride induced-toxicity and changes in the serum sialic acid levels. Food Chem Toxicol. 2010;48:2827–32.View ArticlePubMedGoogle Scholar
- Zhang H, Yu CH, Jiang YP, Peng C, He K, Tang J-Y, Xin H-L. Protective effects of polydatin from polygonum cuspidatum against carbon tetrachloride-induced liver injury in mice. Plos One. 2012;7:e46574.View ArticlePubMedPubMed CentralGoogle Scholar
- Recknagel RO, Jr EA, Dolak GJA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Therap. 1989;43:139–54.View ArticleGoogle Scholar
- Sohn EH, Koo HJ, Hang DTT, Jang S-A, Namkoong S, Lim JD, Kang SC. Protective effects of ellagic acid on ethanol-induced toxicity in hepatic HepG2 cells. Mol Cell Toxicol. 2013;9:249–56.View ArticleGoogle Scholar
- Priyadarsini KI, Khopde SM, Kumar SS, Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J Agric Food Chem. 2002;50:2200–6.View ArticlePubMedGoogle Scholar
- Jeyadevi R, Sivasudha T, Rameshkumar A, Harnly JM, Lin LZ. Phenolic profiling by UPLC-MS/MS and hepatoprotective activity of Cardiospermum halicacabum against CCl4 induced liver injury in Wistar rats. J Funct Foods. 2013;5:289–98.View ArticleGoogle Scholar